RHYTHM PHARMACEUTICALS, INC. RYTM

Rank #2433 · Nasdaq · $6.3B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

18.8

P/E

-34.4

P/B

24.01

ROE

-69.9%

Op. Margin

-238.1%

Debt Ratio

86%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -34.4x, P/B 24.01x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -69.9%. Ranks in the top 92% of the universe.

Safety ★★★☆☆

Good

Debt ratio 86%. Ranks in the top 35% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 227.6% year over year. Ranks in the top 2% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2017	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-1408
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-87
2019	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-43
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	–	19
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	-4629.0	8
2022	$0.0B	$-0.1B	$-0.1B	$0.3B	-4330.2	16
2023	$0.0B	$-0.2B	$-0.1B	$0.2B	-5391.9	71
2024	$0.0B	$-0.2B	$-0.2B	$0.3B	-757.9	57
2025	$0.1B	$-0.2B	$-0.2B	$0.3B	-238.1	86